“We are creating breakthroughs in neurodegeneration. Teva’s National Network of Excellence will contribute to the quality of life of us all.”
“Copaxone and Azilect came from Israeli universities. Why wouldn’t we tap into this incredible expertise and innovation of Israeli Universities to find the next jewels.”
"Our single-minded focus, through the skills of our scientists, is to ensure that we bring essential generic medicines of high quality to the greatest number of in the fastest time possible."
“Today we can understand the processes resultingin disease and response to drugs in individual patients with greater precision than ever before.”
“Our NTE process reflects our expertise ingenerics and specialty drugs, and the synergiescreated when these capabilities are integrated.”
"Our collaboration with Teva will contribute greatly to the Korean pharmaceutical industry by supplying innovative medicines at affordable prices."
“In China there is an increasing demand forquality generic medication. We were very impressedby Teva's oncology, CNS and respiratory portfolio."
“Our DNA is the combination of P&G and Teva. Our mission is to understand what people wantand need, and then find innovative ways to deliver that.”
“We are excited to develop environmentally friendly technologies to create a healthier world for our customers worldwide.“
All News › Top News Jun 27, 2017 Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint Learn More Share Top News Jun 12, 2017 Teva Announces Launch of Generic Zetia® in the United States Learn More Share Top News Jun 9, 2017 Teva Announces Exclusive Launch of Generic Pataday® in the United States Learn More Share Top News Jun 7, 2017 Teva's Fremanezumab Meets all Primary & Secondary Endpoints Across Both Monthly and Quarterly Dosing Regimens in Phase III Study in Episodic Migraine Prevention Learn More Share Top News Jun 6, 2017 Teva to Present at the Jefferies 2017 Global Healthcare Conference Learn More Share
Top News Jun 27, 2017 Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint Learn More
Top News Jun 9, 2017 Teva Announces Exclusive Launch of Generic Pataday® in the United States Learn More
Top News Jun 7, 2017 Teva's Fremanezumab Meets all Primary & Secondary Endpoints Across Both Monthly and Quarterly Dosing Regimens in Phase III Study in Episodic Migraine Prevention Learn More
TAPI Launches Upgraded Customer Portal! TAPI has launched its upgraded customer portal, TAPI Online. This exciting new portal provides full support for API projects, including a range of tools and a comprehensive API document library. Discover more
TAPI has launched its upgraded customer portal, TAPI Online. This exciting new portal provides full support for API projects, including a range of tools and a comprehensive API document library.
Teva's Eva Kopecna Honored Teva's Eva Kopecna wins Contribution award at Organization for Professionals in Regulatory Affairs (TOPRA) Awards. Discover more
Teva's Eva Kopecna wins Contribution award at Organization for Professionals in Regulatory Affairs (TOPRA) Awards.
How Our Uniqueness Creates Healthcare Confidence Around the world, people know that our ultimate goal is their health and well-being. Find out how we do it:
Around the world, people know that our ultimate goal is their health and well-being. Find out how we do it: